Glenmark Pharmaceuticals is preparing to introduce a generic version of sodium phosphates injection in the United States through its wholly owned American subsidiary, aiming to begin distribution in April 2026.
The product has been developed to be therapeutically and bioequivalent to the reference listed drug previously marketed by Hospira Inc., positioning it as an alternative option for hospitals and institutional healthcare providers in the U.S. market.
The planned launch encompasses multiple single-dose vial strengths, including 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL formats, all expected to deliver the same clinical effects as the reference product on which U.S. Food and Drug Administration assessments of safety and effectiveness were based.
Industry sales figures show that, over the 12-month period ending December 2025, sodium phosphates injection USP single-dose vials accounted for roughly USD 66.8 million in annual sales in the United States, reflecting a notable market opportunity for Glenmark’s entry.
The announcement of the upcoming product launch was accompanied by a modest rise in Glenmark’s share price on Indian stock exchanges, underlining investor interest in the company’s expanding generics portfolio within regulated markets.
